Skip to Content
Søk Menu

EAN 2025: GLP-1 Therapy Shows Promise in Reducing Migraine Burden

The GLP-1 receptor agonist liraglutide, used in the treatment of type 2 diabetes, lowers brain fluid pressure. According to a new study presented at the 2025 EAN Congress, liraglutide can cut monthly migraine days by more than half.

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

Marte Helene Bjørk

EAN 2025: First Seizure Clinics – Time Matters in Epilepsy

/ Marte-Helene Bjørk
EAN25Epilepsi Play the Video 11:30
Kristian Steen Frederiksen

EAN 2025: Transforming the Diagnostic Pathway in the Era of Disease-Modifying Therapies for Alzheimer’s Disease

/ Kristian Steen Frederiksen
AlzheimersEAN25 Play the Video 15:47
Nils Erik Gilhus

EAN 2025: A Fundamental Shift in Myasthenia Gravis Treatment on the Horizon

/ Nils Erik Gilhus
EAN25Myasthenia Gravis Play the Video 12:40
Menekse Oeztuerk

EAN 2025: Early Add-On Therapy Shows Benefit in Myasthenia Gravis

/ Menekse Oeztuerk
EAN25Myasthenia Gravis Play the Video 02:57
Rune Häckert Christensen

EAN 2025: Shared Neural Mechanism for Photophobia in Migraine and Post-Traumatic Headache

/ Rune Häckert Christensen
EAN25HodepineMigrene Play the Video 03:43
Nicolò Tedone

EAN 2025: Need for Tailored Assessment and Monitoring of Late-Onset MS

/ Nicolò Tedone
EAN25MS Play the Video 01:36
Frank Jessen

EAN 2025: Patients with Alzheimer’s deserve early diagnosis and causal treatment

/ Frank Jessen
EAN25 Play the Video 03:15
Thomas Clement Truelsen

EAN 2025: Advances and Challenges in Acute Ischemic Stroke

/ Thomas Clement Truelsen
EAN25Stroke Play the Video 04:56
Else Charlotte Sandset

EAN 2025: There are Still a Need for Optimizing Treatment for Ischemic Stroke

/ Else Charlotte Sandset
EAN25Stroke Play the Video 02:32
Back to top